NeoVirTech and VirexpR have joined forces to develop an experimental test bench model of airborne contamination by poxviruses

NeoVirTech and VirexpR have joined forces to develop an experimental test bench model of airborne contamination by poxviruses

“On 14 August, the WHO declared an international public health emergency in response to the growing number of human infections by the monkeypox virus, which could be transmitted by contact, fomites and bioaerosols. This declaration was followed by the publication of Mpox global strategic preparedness and response plan on August 26th”

The VACV ANCHOR poxvirus, developed by NeoVirTech and labeled “used by French Armed Forces” in 2024, is the mimetic model operated by VirexpR to characterize infectious bioaerosols using various test benches with the aim of evaluating the performance of air treatment and analysis technologies and devices under real conditions of use.

NeoVirTech, a biotechnology company developing autofluorescent virus for antiviral discovery and measurement of disinfection procedure, works on poxviruses of human and animal source since more than 10 years. VirexpR is a service company committed to improving the Indoor Air Quality of confined spaces and contributing to national and European sovereignty in terms of protection against emerging and re-emerging infectious diseases.

March 2024, NeoVirTech obtains funding from the AAP France 2030 to develop innovative theranostic platform for cancer virotherapies

NeoVirTech obtains funding from the AAP France 2030 to develop innovative theranostic platform for cancer virotherapies.

NeoVirTech, in partnership with Imactiv-3D, the ImPACT team from the Cancer Research Center of Toulouse and the National Veterinary School of Toulouse, obtains funding from AAP France 2030 organized by the French Government and the Occitanie region for the development of an innovative theranostic platform for cancer virotherapy, in strong collaboration with CHU de Toulouse and Oncopole Claudius Régaud.

This program, called Perseverance, supported by Transgene, aims to accelerate the preclinical development of oncolytic viruses (OV), viruses modified and armed to specifically destroy cancer cells. The program is organized into different work tasks, involving the design of ANCHORTM autofluorescent VO candidates for in vivo monitoring of infection and replication of VOs, their production and validation. ANCHOR™ VOs are then used to perform a virogram on different cancer cell lines to achieve precise mapping of oncolytic activities. The VOs are then optimized and tested for their interaction with pre-existing treatments. Finally, ANCHORTM VOs are tested on organoids derived from patients tumors, the infection of which is analyzed by deep learning and AI processes, and tested on animal models (mouse/rabbit).


At the end of the program, Perseverance offers a clear vision of the efficiency of a given VO on the most relevant models and close to the patient, in order to accelerate their development and guide clinical and therapeutic decisions.

The program is open to any VO of interest, regardless of their stage of development. For more information: contact@neovirtech.com

NeoVirTech SAS and VirexpR SAS create a strategical alliance to combine NeoVirTech’s autofluorescent viruses with VirexpR nebulization technologies for airborne disinfection testing.

NeoVirTech SAS and VirexpR SAS create a strategical alliance to combine NeoVirTech's autofluorescent viruses with VirexpR nebulization technologies for airborne disinfection testing.

What if we could combine our autofluorescent viruses with state of the art nebulization chambers to investigate airborne disinfection? What if we had the ability to measure and visualize if a room has been correctly decontaminated ? What if we could measure viral persistence following airborne dispersion. Well, we can. We are very proud to announce our strategical alliance with VirexpR, the leader in airborne disinfection testing in France. This collaboration will allow NeoVirTech to use VirexpR nebulization room (2,5 and 20m3) to disperse its autofluorescent virus and to measure the efficiency of air treatment devices using an imaged based readout. The alliance provides customer with a unique way to measure and visualize directly airborne disinfection efficiency and efficacy of respiratory protection for example. Contact us to know more : contact@neovirtech.com, contact@virexpr.fr

Picture is presenting VirexpR 2.5 m3 chamber in which NeoVirTech VACV ANCHOR poxvirus was nebulized, recovered using Coriolis aspiration and then confocal microscopy imaged following human cell infection to calculate the number of infectious and replicating particles (green infected cell, blue dot viral DNA, magenta cell marker).

NeoVirTech SAS and BioImmunitas Ltd enter into collaboration to advance BioImmunitas proprietary therapeutic hRP platform on the antiviral market

NeoVirTech SAS and BioImmunitas Ltd enter into collaboration to advance BioImmunitas proprietary therapeutic hRP platform on the antiviral market

NeoVirTech (NVT) and BioImmunitas Ltd enter a long-term partnership to advance a human recombinant protein therapeutic platform from bench to bedside. BioImmunitas Ltd has developed a highly cost-efficient series of recombinant proteins which form the platform therapeutic agent. This highly innovative treatment has been shown to be efficacious in several different therapeutic areas. Their collaboration with NeoVirTech has seen BioImmunitas utilize NVT’s proprietary antiviral discovery platform to position its own therapeutic hRPP on the anti-viral market.

NeoVirTech opens a new laboratory at the Toulouse Cancer Research Center (CRCT)

NeoVirTech opens a new laboratory at the Toulouse Cancer Research Center (CRCT)

NeoVirTech SAS opens a new laboratory at the Toulouse Cancer Research Center (CRCT) to structure its anti-cancer programs towards the creation of a patient-oriented theranostics platform, and to promote drug development

NeoVirTech provides access to its ANCHORTM technology platform to develop disruptive models for the investigation of cancer-associated mechanisms and the preclinical development of oncolytic virotherapies.

More specifically, NeoVirTech and CRCT Team 10 aim to develop a rapid and reliable theranostic platform to ensure the efficacy of oncolytic virotherapies in cancer patients.

Long-term collaboration will ensure patient benefits and reduce the time to decision for individualised cancer therapies.

We are pleased to announce our partnership with VirHealth!

We are pleased to announce our partnership with VirHealth!

VirHealth SAS and NeoVirTech SAS announce the creation of a strategical alliance to create one of the most advanced private virus disinfection platform in Europe.


VirHealth and NeoVirTech join their virology expertise to provide customers one of the most extended virus disinfection measurement and R&D platform in France and in Europe. This alliance will allow the partners to combine their respective expertise in an integrated offer dedicated to increase knowledge in virus persistence in the environment, virus disinfection procedure and to provide customer state of the art models for the measurement of disinfection procedures using innovative and standardized approaches.